ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Change of bowel habit,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
2,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2,2,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
3,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
4,1,Product package associated injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
5,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
5,2,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
5,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
5,4,Throat irritation,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
6,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
7,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
